Moderna Inc. plans to develop and begin testing vaccines targeting 15 of the world’s most worrisome pathogens by 2025 and will permanently waive the company’s COVID-19 vaccine patents for shots intended for certain low-income and middle-income countries.
Biopharma Industry News: Update on the Novel Coronavirus
3D, Antivirals, Business, Clinical Trials, Coronavirus Disease (COVID-19) Pandemic, FDA, FDA/Regulatory, Genomics, Laboratory, MERS, Messenger RNA (mRNA) Vaccines, Partnerships, Plasma, R&D, SARS, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), TestsA summary of daily biopharma industry news regarding the novel coronavirus trending on March 27, 2020, with the FDA now working with 220 test developers.